Tracers / [177Lu]Lu-DOTA-FD3
[177Lu]Lu-DOTA-FD3
Also written as [Lu-177]Lu-DOTA-FD3
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- FAP-targeted peptide, DOTA-conjugated (FD3)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 38706713
- Clinical application
- Radioligand therapy of FAP-overexpressing tumors PMID 38706713
- Theranostic pair
- <a href="/tracers/ga68-dotafd3/">ga68-dotafd3</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | — | >99% | FD3 | 38706713 2023 Research (Wash D C) 177LuCl3 solution (555 MBq in 0.04 M HCl) was added to 500 μl of 1M NH4OAC (pH = 5), followed by the addition of 375 nmol of FD1, FD2, or FD3. The solution was shaken at a temperature of 100 °C for a duration of 30 min. |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-FD3, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38706713. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38706713: 'followed by the addition of 375 nmol of FD1, FD2, or FD3'.